Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Lowered to Strong Sell Rating by Jefferies Financial Group

Jefferies Financial Group downgraded shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) from a moderate sell rating to a strong sell rating in a research report released on Tuesday morning,Zacks.com reports.

Several other analysts also recently commented on FMS. Zacks Research downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 4th. Truist Financial set a $28.00 price objective on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Monday, January 5th. Erste Group Bank cut Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 5th. Morgan Stanley reaffirmed an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Tuesday, January 27th. Finally, The Goldman Sachs Group cut Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “neutral” rating in a report on Tuesday, January 20th. Five investment analysts have rated the stock with a Hold rating and four have assigned a Sell rating to the company. According to data from MarketBeat, Fresenius Medical Care AG & Co. KGaA currently has an average rating of “Reduce” and an average price target of $28.00.

Fresenius Medical Care AG & Co. KGaA Stock Up 0.2%

FMS stock opened at $22.70 on Tuesday. Fresenius Medical Care AG & Co. KGaA has a 1-year low of $20.94 and a 1-year high of $30.46. The business’s 50 day simple moving average is $23.30 and its 200 day simple moving average is $24.46. The company has a current ratio of 1.36, a quick ratio of 1.00 and a debt-to-equity ratio of 0.45. The firm has a market capitalization of $13.16 billion, a PE ratio of 11.88, a PEG ratio of 0.72 and a beta of 0.90.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last released its quarterly earnings data on Tuesday, February 24th. The company reported $0.83 EPS for the quarter, topping analysts’ consensus estimates of $0.67 by $0.16. Fresenius Medical Care AG & Co. KGaA had a net margin of 5.03% and a return on equity of 8.71%. The firm had revenue of $5.95 billion during the quarter, compared to analysts’ expectations of $4.80 billion. As a group, research analysts anticipate that Fresenius Medical Care AG & Co. KGaA will post 1.51 EPS for the current year.

Institutional Trading of Fresenius Medical Care AG & Co. KGaA

Several large investors have recently modified their holdings of the stock. TD Waterhouse Canada Inc. bought a new position in shares of Fresenius Medical Care AG & Co. KGaA in the second quarter worth $36,000. CIBC Private Wealth Group LLC grew its stake in Fresenius Medical Care AG & Co. KGaA by 398.2% during the third quarter. CIBC Private Wealth Group LLC now owns 1,380 shares of the company’s stock worth $36,000 after buying an additional 1,103 shares in the last quarter. Atlantic Union Bankshares Corp bought a new position in Fresenius Medical Care AG & Co. KGaA in the 2nd quarter valued at about $43,000. Arax Advisory Partners raised its position in shares of Fresenius Medical Care AG & Co. KGaA by 121.6% in the 4th quarter. Arax Advisory Partners now owns 1,613 shares of the company’s stock valued at $38,000 after buying an additional 885 shares in the last quarter. Finally, Kestra Advisory Services LLC acquired a new position in shares of Fresenius Medical Care AG & Co. KGaA in the 4th quarter valued at approximately $48,000. 8.37% of the stock is owned by institutional investors and hedge funds.

Key Fresenius Medical Care AG & Co. KGaA News

Here are the key news stories impacting Fresenius Medical Care AG & Co. KGaA this week:

• Positive Sentiment: Q4 earnings and revenue materially beat expectations, EPS and margins expanded (driven by FME25+ cost savings), supporting improved profitability and investor confidence. Article Title
• Positive Sentiment: Company reported strong full‑year 2025 results: ~27% earnings growth, operating income at the top end of outlook, reported net income and EPS up sharply, and an accelerated share‑buyback program plus a planned dividend increase — all supportive of future EPS and capital return. Article Title
• Positive Sentiment: Short interest fell sharply in February (down ~20.6% month over month to ~1.85M shares), lowering near‑term bearish pressure and reducing the potential for short‑squeeze volatility.
• Neutral Sentiment: Management updated FY‑2026 guidance with higher revenue targets (company cited ~$23.8B vs. consensus ~$22.6B), but the outlook commentary contained caveats about headwinds; investors will focus on detailed guidance and margins. Article Title
• Neutral Sentiment: Full Q4 earnings call transcript and presentation are available for details on regional performance, reimbursement assumptions and timing of cost savings — useful for investors assessing sustainability of margin gains. Earnings Call Transcript Presentation
• Negative Sentiment: Despite strong headline numbers, the stock reacted negatively to a cautious tone on the outlook and weaker U.S. operational performance; media reported share declines after management commentary. Article Title
• Negative Sentiment: Analyst/commentary pieces highlighted the drop in the share price (one article quantified a ~6.7% decline) and pointed to investor concerns around U.S. growth and the sustainability of margin improvements. Article Title

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.